Synageva BioPharma Expands International Clinical Trial for Infants with Lysosomal Acid Lipase Deficiency, a Lysosomal Storage Disorder

Published: Sep 28, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), announced today that it has expanded its ongoing clinical trial for infants with Lysosomal Acid Lipase (“LAL”) Deficiency to the United States. This global clinical trial is open for enrollment at multiple sites. LAL Deficiency, a Lysosomal Storage Disorder (LSD), is also known as Wolman Disease or Cholesteryl Ester Storage Disease (CESD) and is a rare, autosomal recessive, progressive disease with devastating consequences for infants, children and adults.

Back to news